Plain-English translation of NCT06932757 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called to see if it can prevent uveal melanoma—a serious type of eye cancer—from spreading after your primary tumor has been removed or treated with radiation. You would take this medication over about a year while researchers monitor whether it helps reduce your risk of the cancer coming back or spreading to other parts of your body.
Uveal melanoma can be life-threatening because it often spreads to the liver and other organs even after the eye tumor is successfully treated. This trial is testing whether this medication can help prevent that spread and improve survival in patients at highest risk.
You likely qualify if…
You likely don't qualify if…
You would take the medication by mouth for up to 17 cycles, with each cycle lasting 3 weeks, for a total of about 51 weeks. After you finish taking the medication, you would return for follow-up visits and monitoring for up to 2 years to check whether your cancer has returned or spread. Your total time in the study would be about 3 years from start to finish.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
University of Miami
Collaborators
Viriom, Joseph and Florence Mandel Family Foundation
Enrollment target
~63 participants
Started
May 2025
Primary completion
May 2030
Age range
19 Years and older
Last updated on clinicaltrials.gov in June 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Christine Estevez
University of Miami
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.